指南与共识抗菌药物管理治疗药物监测与药物基因组学

国际共识聚焦更新:重症成人患者延长输注β-内酰胺类抗生素

Focused Update to International Consensus Recommendations for the Use of Prolonged-Infusion Beta-Lactam Antibiotics Among Severely Ill Adult Patients: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of
指南 / 共识 · Pharmacotherapy · 2026-01-01

该聚焦更新基于28项评估死亡率的RCT和21项评估临床治愈的RCT,重新评价重症成人患者延长输注对比短输注β-内酰胺类的疗效。汇总分析显示延长输注降低死亡率(RR 0.91;95%CI 0.85-0.97)并提高临床治愈(RR 1.11;95%CI 1.06-1.17),证据确定性分别提升至中等和低。

要点

  • 重症成人患者延长输注β-内酰胺类可改善生存和临床治愈。
  • 开始持续输注时建议使用负荷剂量。
  • 未来需明确最可能获益亚群和TDM角色。

核心结论

  • 累积证据强化并支持重症成人患者使用延长输注β-内酰胺类以改善生存和临床治愈。

研究设计与样本

  • 对原国际共识推荐进行聚焦更新,采用与原指南一致的研究识别、筛选和证据分级方法,并增加贝叶斯荟萃分析。
  • 共分析28项评估死亡率的RCT和21项评估临床治愈的RCT,对象为重症成人患者。

主要发现

  • 28项RCT汇总显示延长输注降低死亡率(RR 0.91;95%CI 0.85-0.97),贝叶斯分析显示获益后验概率98.76%。
  • 21项RCT汇总显示延长输注提高临床治愈(RR 1.11;95%CI 1.06-1.17),贝叶斯分析显示获益后验概率99.97%。
  • 证据确定性:死亡率为中等,临床治愈为低。
  • 亚组分析评估负荷剂量,提示连续输注前使用负荷剂量可改善结局。

关键数值与推荐

  • 推荐重症成人患者使用延长输注β-内酰胺类而非短输注,以改善死亡率或临床治愈。
  • 建议在开始持续输注治疗时使用负荷剂量。

临床怎么用

  • 对重症成人患者优先选择延长输注β-内酰胺类方案。
  • 启动持续输注时给予负荷剂量。

局限性

  • 临床治愈证据确定性仍为低。
  • 未来需识别最可能获益亚群、明确最佳延长输注策略及治疗药物监测的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2023, international consensus recommendations suggested the use of prolonged-infusion beta-lactam antibiotics over short-infusion dosing in severely ill adult patients to improve mortality or clinical cure, although the certainty of evidence was very low. With the availability of several new randomized controlled trials (RCTs), this focused update re-evaluates the efficacy of prolonged versus short infusion among severely ill adult patients. The original Population, Intervention, Comparator, and Outcome (PICO) question VII was separated into two questions addressing mortality (VIIa) and clinical cure (VIIb). Methods used for study identification, screening, and evidence grading were consistent with the original guideline, with the addition of Bayesian meta-analyses. A total of 28 RCTs evaluating mortality in severely ill adults were analyzed, with pooled estimates favoring prolonged infusion (RR 0.91; 95% confidence interval 0.85 to 0.97), supported by Bayesian analyses demonstrating a 98.76% posterior probability of benefit. Across 21 RCTs evaluating clinical cure, prolonged infusion improved outcomes compared with short infusion (RR 1.11; 95% confidence interval 1.06 to 1.17), supported by Bayesian analyses demonstrating a 99.97% posterior probability of benefit. Certainty of evidence was strengthened to moderate for mortality and low for clinical cure. Consistent with the original recommendation (PICO X), subgroup analyses evaluating loading doses suggested improved outcomes when a loading dose is used before continuous infusion. Overall, the cumulative evidence reinforces and strengthens the recommendation for use of prolonged-infusion beta-lactam therapy in severely ill adult patients to improve survival and clinical cure. Continued use of loading doses when initiating continuous-infusion therapy is suggested. Future research should identify subpopulations most likely to benefit, clarify optimal prolonged-infusion strategies, and define the role of therapeutic drug monitoring.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Hong LT, FakhriRavari A, Ulldemolins M, et al. Focused Update to International Consensus Recommendations for the Use of Prolonged-Infusion Beta-Lactam Antibiotics Among Severely Ill Adult Patients: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2026. PMID: 42598847. doi:10.1002/phar.70188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。